Nab-Paclitaxel for Relapsed AIDS-Related Kaposi Sarcoma -A Case Report.
HIV
Kaposi sarcoma
case report
nab-paclitaxel
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2024
2024
Historique:
received:
10
01
2024
accepted:
23
03
2024
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
16
4
2024
Statut:
epublish
Résumé
Kaposi sarcoma (KS) incidence has decreased since the initiation of combination antiretroviral therapy (cART), but it remains the most common cancer in people with HIV/AIDS (PWHA). PWHA with advanced immunosuppression who initiate antiretroviral therapy are susceptible to the occurrence of an immune reconstitution inflammatory syndrome (IRIS). This report covers the case of a 25-year-old male with AIDS-related KS who relapsed after Liposomal Doxorubicin, but recovered well after administration of nab-paclitaxel (Nab-PTX). This is a rare case in choosing Nab-PTX to treat relapsed AIDS-KS and get good feedback. We report the case to provide a possible solution to treat AIDS-KS.
Identifiants
pubmed: 38623529
doi: 10.2147/IDR.S456286
pii: 456286
pmc: PMC11017983
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1431-1437Informations de copyright
© 2024 Yu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests in this work.